An Open Positron Emission Tomography Study to Assess the Effects of Varying Mass of AZD4694 on Radioligand Binding Parameters in Healthy Volunteers and Patients With Alzheimer's Disease

NCT ID: NCT01325402

Last Updated: 2012-12-10

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 16 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-08-31
• Study Completion Date: 2012-11-30

Brief Summary

In this study different mass of the radioligand AZD4694 will be given to patients with Alzheimer's Disease and healthy volunteers to evaluate wich Mass of AZD4694 that gives the best opportunities for following disease progress and treatment effects.

Detailed Description

Open-Label Positron Emission Tomography Study with Selective Beta Amyloid Radioligand (18Fluor)AZD4694 to Assess the Effects of Varying Mass of AZD4694 on Radioligand Binding Parameters in Healthy Volunteers and Patients with Alzheimer's Disease

Conditions

Maximum Diagnostic Mass of [18Fluor]AZD4694

Keywords

Radioligand; Alzheimers disease; Maximum Diagnostic Mass; Beta amyloid

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

Part 1 Cohort 1

Patients with mild to moderate Alzheimer's Disease

Group Type: EXPERIMENTAL

[18Fluor]AZD4694

Intervention Type: OTHER

Low mass dose below 5ug. High mass dose around 40 and 50 ug.

Part 1 Cohort 2

Patients with mild to moderate Alzheimer's Disease. To run if Maximum Detective Mass is detected in cohort 1.

Group Type: EXPERIMENTAL

[18Fluor]AZD4694

Intervention Type: OTHER

Low mass dose below 5ug. High mass dose around 20 ug.

Part 2

Healthy Volunteers

Group Type: EXPERIMENTAL

[18Fluor]AZD4694

Intervention Type: OTHER

Low mass dose below 5ug. High mass dose will be the Maximum Detective Mass established in the previous panels.

Interventions

[18Fluor]AZD4694

Low mass dose below 5ug. High mass dose around 40 and 50 ug.

Intervention Type: OTHER

[18Fluor]AZD4694

Low mass dose below 5ug. High mass dose around 20 ug.

Intervention Type: OTHER

[18Fluor]AZD4694

Low mass dose below 5ug. High mass dose will be the Maximum Detective Mass established in the previous panels.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Body Mass Index between 18 and 30 kg/m2 and weigh at least 50kg and no more than 100 kg.
• Mini Mental State Examination score >28 (healthy volunteers only)
• Mini Mental State Examination score 16-28 (Alzheimer's Disease patients only)
• Hachinski Ischemic Score =4 (Alzheimer's Disease patients only)
• Clinical diagnosis of probable Alzheimer's Disease according to National Institute of Neurology and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association criteria (Alzheimer's Disease patients only)

Exclusion Criteria

• Significant Neurological disease or dementia, as defined clinically or by imaging, other than Alzheimer's Disease that may affect cognition or ability to complete the study (Alzheimer's Disease patients only).
• Possible, probable or definite vascular dementia in accordance with the National Institute of neurology and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders association criteria (Alzheimer's Disease patients only).
• Current major depressive disorder or other major psychiatric disorders according to Diagnostic and Statistical Manual of Mental Disorders, edition 4, American Psychiatric Association 1994 criteria (Alzheimer's disease patients only).
• Depression: Cornell Depression Rating >9 (Alzheimer's disease patients only).
• Abnormal vital signs defined as any of the following: Systolic blood pressure >180 mmHg, Diastolic blood pressure >90 mmHg, heart rate <40 or>85 beats per minute (Alzheimer's disease patients only).
• Myocardial infarction or acute coronary syndrome within the last year (Alzheimer's disease patients only).
• Had Positron Emission Tomography measurements for scientific purposes within the last 12 months.
• History of any clinically significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study (healthy volunteers only).
• History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs (healthy volunteers only).
• History of previous (within the last 5 years) or ongoing psychiatric disease/condition including psychosis, affective disorder, anxiety disorder, borderline state and personality disorder according to the criteria in to Diagnostic and Statistical Manual of Mental Disorders, edition 4, American Psychiatric Association 1994, as assessed by the Mini international neuropsychiatric interview (healthy volunteers only).
• Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the first administration of Investigational Product (healthy volunteers only).
• Any clinically significant abnormalities in clinical chemistry, haematology or urinalysis results as judged by the investigator (healthy volunteers only).
• Healthy volunteers<65 years: abnormal vital signs defined as any of the following: Systolic blood pressure >140 mmHg, Diastolic blood pressure >90 mmHg, heart rate <40 or>85 beats per minute.
• Healthy volunteers≥65 years: abnormal vital signs defined as any of the following: Systolic blood pressure >160 mmHg, Diastolic blood pressure >90 mmHg, heart rate <40 or >85 beats per minute.
• Central Nervous system infarct, infection of focal lesions of clinical significance on MRI scans as judged by the investigator.

• Minimum Eligible Age: 50 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

AstraZeneca

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Bjorn Paulsson

Role: STUDY_DIRECTOR

AstraZeneca

Niels Andreasen, MD

Role: PRINCIPAL_INVESTIGATOR

Geriatric clinic Karolinska University Hospital Huddinge

Elisabeth Eden, MD

Role: PRINCIPAL_INVESTIGATOR

Quintiles Aktiebolag

Locations

Research Site

Stockholm, , Sweden

Research Site

Uppsala, , Sweden

Countries

Sweden

Other Identifiers

EudraCT # 2011-000095-34

Identifier Type: -

Identifier Source: secondary_id

D2750C00002

Identifier Type: -

Identifier Source: org_study_id